Brenda M. Sandmaier
Experienced in Myelofibrosis

Dr. Brenda M. Sandmaier

Hematology Oncology | Oncology
The Association Of University Physicians
1959 Ne Pacific St, 
Seattle, WA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
39 Years of Experience
Experienced in Myelofibrosis
The Association Of University Physicians
1959 Ne Pacific St, 
Seattle, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Brenda Sandmaier is a Hematologist Oncology specialist and an Oncologist in Seattle, Washington. Dr. Sandmaier has been practicing medicine for over 39 years and is rated as an Experienced provider by MediFind in the treatment of Myelofibrosis. Her top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Bone Graft. Dr. Sandmaier is currently accepting new patients.

Her clinical research consists of co-authoring 206 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 3 articles and participated in 1 clinical trial in the study of Myelofibrosis.

Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in WA
Languages Spoken
English
Arabic
Castilian
Punjabi
Russian
Spanish
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO

Locations

THE ASSOCIATION OF UNIVERSITY PHYSICIANS
1959 Ne Pacific St, Seattle, WA 98195

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Study Evaluating Escalating Doses of 211^At-Labeled Anti-CD45 MAb BC8-B10 (211^At-BC8-B10) Followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS)
A Study Evaluating Escalating Doses of 211^At-Labeled Anti-CD45 MAb BC8-B10 (211^At-BC8-B10) Followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS)
Enrollment Status: Recruiting
Publish Date: June 18, 2025
Intervention Type: Radiation, Drug, Procedure
Study Drugs: Cyclosporine, Fludarabine, Mycophenolate Mofetil, Sirolimus
Study Phase: Phase 1/Phase 2
A Phase 1/2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells After Partially Mismatched, Related, T Cell-Depleted HSCT (Hematopoietic Stem Cell Transplant)
A Phase 1/2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells After Partially Mismatched, Related, T Cell-Depleted HSCT (Hematopoietic Stem Cell Transplant)
Enrollment Status: Active_not_recruiting
Publish Date: July 12, 2022
Intervention Type: Biological, Drug, Procedure
Study Drugs: BPX-501, Rimiducid
Study Phase: Phase 1/Phase 2
A Phase I Study of Donor BPX-501 T Cell Infusion for Adults With Recurrent or Minimal Residual Disease Hematologic Malignancies Post-Allogeneic Transplant
A Phase I Study of Donor BPX-501 T Cell Infusion for Adults With Recurrent or Minimal Residual Disease Hematologic Malignancies Post-Allogeneic Transplant
Enrollment Status: Active_not_recruiting
Publish Date: July 12, 2022
Intervention Type: Biological, Drug
Study Drugs: BPX-501, Rimiducid
Study Phase: Phase 1
A Phase II Study of Optimally Dosed Clofarabine in Combination With Low-Dose TBI to Decrease Relapse Rates After Related or Unrelated Donor Hematopoietic Cell Transplantation in Patients With AML
A Phase II Study of Optimally Dosed Clofarabine in Combination With Low-Dose TBI to Decrease Relapse Rates After Related or Unrelated Donor Hematopoietic Cell Transplantation in Patients With AML
Enrollment Status: Completed
Publish Date: April 16, 2020
Intervention Type: Drug, Procedure, Radiation, Other
Study Phase: Phase 2
Low-Dose TBI Dose Escalation to Decrease Risks of Progression and Graft Rejection After Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning as Treatment for Untreated Myelodysplastic Syndrome or Myeloproliferative Disorders - A Multi-Center Trial
Low-Dose TBI Dose Escalation to Decrease Risks of Progression and Graft Rejection After Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning as Treatment for Untreated Myelodysplastic Syndrome or Myeloproliferative Disorders - A Multi-Center Trial
Enrollment Status: Completed
Publish Date: January 31, 2020
Intervention Type: Radiation, Procedure, Drug, Other
Study Phase: Phase 2
A Study Evaluating Escalating Doses of 90Y-DOTA-BC8 (Anti-CD45) Antibody Followed by Allogeneic Stem Cell Transplantation for High-Risk Acute Myeloid Leukemia (AML) Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS)
A Study Evaluating Escalating Doses of 90Y-DOTA-BC8 (Anti-CD45) Antibody Followed by Allogeneic Stem Cell Transplantation for High-Risk Acute Myeloid Leukemia (AML) Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS)
Enrollment Status: Completed
Publish Date: December 10, 2019
Intervention Type: Radiation, Drug, Procedure, Biological, Other
Study Phase: Phase 1
A Phase II Study to Assess Immunosuppression With Sirolimus Combined With Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) for Prevention of Acute GVHD After Non-Myeloablative HLA Class I or II Mismatched Donor Hematopoietic Cell Transplantation- A Multi-Center Trial
A Phase II Study to Assess Immunosuppression With Sirolimus Combined With Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) for Prevention of Acute GVHD After Non-Myeloablative HLA Class I or II Mismatched Donor Hematopoietic Cell Transplantation- A Multi-Center Trial
Enrollment Status: Completed
Publish Date: December 09, 2019
Intervention Type: Drug, Radiation, Other, Procedure
Study Phase: Phase 2
A Phase 1/2 Study of Vadastuximab Talirine Administered in Sequence With Allogeneic Hematopoietic Stem Cell Transplant in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
A Phase 1/2 Study of Vadastuximab Talirine Administered in Sequence With Allogeneic Hematopoietic Stem Cell Transplant in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Enrollment Status: Terminated
Publish Date: January 09, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 7 Less Clinical Trials

206 Total Publications

Salvage Allogeneic Hematopoietic Cell Transplantation for Primary Graft Failure.
Salvage Allogeneic Hematopoietic Cell Transplantation for Primary Graft Failure.
Journal: Transplantation and cellular therapy
Published: October 09, 2025
Similar Doctors
Elite in Myelofibrosis
Dr. Rachel B. Salit
Hematology Oncology | Hematology | Oncology
Elite in Myelofibrosis
Dr. Rachel B. Salit
Hematology Oncology | Hematology | Oncology

The Association Of University Physicians

825 Eastlake Ave E, 
Seattle, WA 
 (1.9 miles away)
206-288-1000
Languages Spoken:
English, German, Mandarin, Vietnamese
See accepted insurances
Accepting New Patients
Offers Telehealth

Rachel Salit is a Hematologist Oncology specialist and a Hematologist in Seattle, Washington. Dr. Salit is rated as a Distinguished provider by MediFind in the treatment of Myelofibrosis. Her top areas of expertise are Myelofibrosis, Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), and Bone Marrow Transplant. Dr. Salit is currently accepting new patients.

Distinguished in Myelofibrosis
Dr. Anna B. Halpern
Hematology Oncology | Hematology | Oncology
Distinguished in Myelofibrosis
Dr. Anna B. Halpern
Hematology Oncology | Hematology | Oncology

The Association Of University Physicians

825 Eastlake Ave E, 
Seattle, WA 
 (1.9 miles away)
206-288-1000
Languages Spoken:
English, Hindi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Anna Halpern is a Hematologist Oncology specialist and a Hematologist in Seattle, Washington. Dr. Halpern is rated as a Distinguished provider by MediFind in the treatment of Myelofibrosis. Her top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Chronic Myelomonocytic Leukemia (CMML), and Bone Marrow Aspiration. Dr. Halpern is currently accepting new patients.

Advanced in Myelofibrosis
Dr. Jack W. Singer
Hematology Oncology
Advanced in Myelofibrosis
Dr. Jack W. Singer
Hematology Oncology
Harborview Medical Center, 325 9th Ave, 
Seattle, WA 
 (3.3 miles away)
206-731-3000
Languages Spoken:
English

Jack Singer is a Hematologist Oncology provider in Seattle, Washington. Dr. Singer is rated as an Advanced provider by MediFind in the treatment of Myelofibrosis. His top areas of expertise are Myelofibrosis, Non-Hodgkin Lymphoma, Splenomegaly, and Thrombocytopenia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sandmaier's expertise for a condition
ConditionClose
View All 23 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile